HTA decision-making for drugs for rare diseases: comparison of processes across countries

INTRODUCTION: Drugs for rare diseases (DRDs) offer important health benefits, but challenge traditional health technology assessment, reimbursement, and pricing processes due to limited effectiveness evidence. Recently, modified processes to address these challenges while improving patient access ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Stafinski, Tania, Glennie, Judith, Young, Andrea, Menon, Devidas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264608/
https://www.ncbi.nlm.nih.gov/pubmed/35804398
http://dx.doi.org/10.1186/s13023-022-02397-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264608/
https://www.ncbi.nlm.nih.gov/pubmed/35804398
http://dx.doi.org/10.1186/s13023-022-02397-4

Ejemplares similares